Development and Validation of an HPLC Method for the Simultaneous Determination of Eight Related Substances in Fosaprepitant Dimeglumine API

被引:0
作者
Cao, Zhiling [1 ]
Zhang, Ling [1 ]
Huang, Maolong [1 ]
Xia, Siyi [1 ]
Sun, Yuhan [1 ]
Yu, Xudong [1 ]
Shi, Dahua [1 ]
Zhu, Jian [1 ]
Xu, Fan [1 ]
机构
[1] Jiangsu Ocean Univ, Jiangsu Inst Marine Resources, Coinnovat Ctr Jiangsu Marine Bioind Technol, Jiangsu Key Lab Marine Pharmaceut Cpd Screening, Lianyungang 222005, Peoples R China
关键词
Fosaprepitant dimeglumine (FOSD); Impurities; Related substances; HPLC; Validation; CHEMOTHERAPY-INDUCED NAUSEA; APREPITANT; IMPURITY; PREVENTION; STABILITY; EFFICACY;
D O I
10.1007/s10337-025-04389-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of this study was to develop and validate a robust, precise, and selective high-performance liquid chromatography (HPLC) method for the separation and determination of related impurities in fosaprepitant dimeglumine API. The chromatographic separation was performed on a Supersil ODS-2 column (250 x 4.6 mm, 5 mu m) at a wavelength of 215 nm using a mixture of phosphate buffer (pH 2.15) and acetonitrile as the mobile phase in gradient elution mode. The validation results demonstrate that the method exhibits acceptable specificity, linearity, accuracy, precision, and robustness. The detection limits and quantitation limits ranged from 1.5 to 12.5 ng mL-1 and from 3.0 to 37.5 ng mL-1, respectively. A linear relationship was observed between the peak area and concentration of fosaprepitant and its eight related impurities with a correlation coefficient value of r2 >= 0.999. The analysis of commercial fosaprepitant dimeglumine products revealed a significantly higher purity than expected, with all known impurities falling below specification limits. The new HPLC method has been successfully applied to analyze commercial bulk drug samples and is suitable for quality-control laboratories for both qualitative and quantitative assessment of eight related substances in the fosaprepitant dimeglumine API.
引用
收藏
页码:205 / 214
页数:10
相关论文
共 25 条
[1]   Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety [J].
Aapro, Matti ;
Carides, Alexandra ;
Rapoport, Bernardo L. ;
Schmoll, Hans-Joachim ;
Zhang, Li ;
Warr, David .
ONCOLOGIST, 2015, 20 (04) :450-458
[2]   An Overview of Advances in the Chromatography of Drugs Impurity Profiling [J].
ALSaeedy, Mohammed ;
Al-Adhreai, Arwa ;
Oncu-Kaya, Elif Mine ;
Sener, Erol .
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2022, 53 (07) :1455-1471
[3]  
[Anonymous], 2005, VAL AN PROC TEXT MET
[4]   SEPARATION AND QUANTIFICATION OF PROCESS RELATED IMPURITIES AND DIASTEREOMERS IN APREPITANT BULK DRUG SUBSTANCE [J].
Ashok, Sigala ;
Raghunadhababu, C. V. ;
Varma, M. Satish ;
Balaswamy, G. .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2012, 35 (05) :677-687
[5]  
Bhatt NG, Patent, Patent No. [US8623844, 8623844]
[6]   Pharmacokinetic evaluation of fosaprepitant dimeglumine [J].
Colon-Gonzalez, Francheska ;
Kraft, Walter K. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (10) :1277-1286
[7]   Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy [J].
Gao, Ai ;
Guan, Shasha ;
Sun, Yinjuan ;
Wang, Lingling ;
Meng, Fanlu ;
Liu, Xia ;
Gu, Liyan ;
Li, Guo ;
Zhong, Diansheng ;
Zhang, Linlin .
BMC CANCER, 2023, 23 (01)
[8]   Critical review of reports on impurity and degradation product profiling in the last decade [J].
Gorog, Sandor .
TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2018, 101 :2-16
[9]  
Harron D W. G., 2013, Technical Requirements for Registration of Pharmaceuticals for Human Use: The ICH Process, The Textbook of Pharmaceutical Medicine, pag, P447, DOI [DOI 10.1002/9781118532331.CH23, 10.1002/9781118532331.ch23]
[10]   Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE) [J].
Hata, Akito ;
Shiraishi, Yoshimasa ;
Inui, Naoki ;
Okada, Morihito ;
Morise, Masahiro ;
Akiyoshi, Kohei ;
Takeda, Masayuki ;
Watanabe, Yasutaka ;
Sugawara, Shunichi ;
Shinagawa, Naofumi ;
Kubota, Kaoru ;
Saeki, Toshiaki ;
Tamura, Tomohide .
ONCOLOGY AND THERAPY, 2022, 10 (01) :253-262